https://www.jubilanttx.com 2026-07-22T21:17:07+00:00 1 https://www.jubilanttx.com/search 2025-07-15T14:41:23+00:00 0.8 https://www.jubilanttx.com/company-policies 2026-06-03T22:18:48+00:00 0.8 https://www.jubilanttx.com/connect 2026-06-03T22:01:57+00:00 0.8 https://www.jubilanttx.com/disclaimer 2026-06-03T22:19:05+00:00 0.8 https://www.jubilanttx.com/expanded-access-policy 2026-06-04T16:58:59+00:00 0.8 https://www.jubilanttx.com/our-pipeline 2026-07-13T16:53:12+00:00 0.8 https://www.jubilanttx.com/our-science 2026-06-03T21:47:57+00:00 0.8 https://www.jubilanttx.com/privacy-policy 2026-07-16T14:30:53+00:00 0.8 https://www.jubilanttx.com/about-us 2026-07-22T21:17:40+00:00 0.8 https://www.jubilanttx.com/about-us/news 2026-07-13T15:58:20+00:00 0.8 https://www.jubilanttx.com/our-pipeline/publications 2026-06-03T21:57:06+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-presents-preclinical-data-at-the-american-association-for-cancer-research 2026-05-20T02:45:48+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-strengthens-scientific-advisory-board 2026-05-20T02:44:24+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-to-participate-in-upcoming-investor-conferences 2026-05-20T02:43:32+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-and-onethree-biotech-collaborate-to-advance-precision-oncology 2026-05-20T02:42:32+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-upcoming-presentation-at-2020-ash-virtual-annual-meeting 2026-05-20T02:38:25+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-efficacy-and-biomarker-data-at-62nd-ash-annual-meeting-for-its-novel-dual-lsd1-hdac6-inhibitor-for-the-treatment-of-hematological-cancers 2026-05-20T02:36:59+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-research-collaboration-with-the-wistar-institute-to-evaluate-the-activity-of-novel-pad4-inhibitors-to-reduce-clinical-severity-of-covid-19 2026-05-20T02:34:04+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-appoints-dr-robert-glassman-to-its-board-of-directors 2026-05-20T02:31:29+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-research-collaboration-with-boston-childrens-hospital-harvard-medical-school-to-evaluate-pad4-inhibitors-in-autoimmuneinflammation-disease-models 2026-05-20T02:22:53+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-appointment-of-luca-rastelli-phd-as-chief-scientific-officer 2026-05-20T02:47:15+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-presents-preclinical-data-on-its-brain-penetrant-prmt5-inhibitor-and-small-molecule-pd-l1-inhibitor-at-the-american-association-for-cancer-research-aacr-annual-meeting-2021 2026-05-20T02:17:39+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-strengthens-board-of-directors-with-addition-of-leila-alland-md-and-announces-appointment-of-jeremy-barton-md-as-strategic-advisor-and-interim-cmo 2026-05-20T02:10:07+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-for-its-novel-dual-lsd1-and-hdac6-inhibitor-jb1-802 2026-05-20T02:02:25+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-to-participate-and-present-at-upcoming-investor-conferences 2026-05-20T02:01:40+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-announces-fda-clearance-of-ind-for-jbi-802-a-novel-dual-lsd1-and-hdac6-inhibitor-for-treatment-of-solid-tumors 2026-05-20T01:58:32+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-to-present-data-on-isoform-selective-pad4-inhibitors-in-the-treatment-of-cancer-at-the-american-association-of-cancer-research-annual-aacr-meeting-2022 2026-05-20T01:57:30+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-reports-isoform-selective-pad4-inhibitors-demonstrating-high-in-vitro-selectivity-and-potency-and-in-vivo-oral-bioavailability-and-anti-tumor-activity 2026-05-20T01:55:12+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-doses-first-patient-in-phase-iii-trial-evaluating-jbi-802-dual-inhibitor-of-lsd1-and-hdac6-in-patients-with-advanced-solid-tumors 2026-05-20T01:50:17+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-reports-development-of-orally-available-and-brain-penetrant-small-molecule-inhibitors-of-pd-l1-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting 2026-05-20T01:48:47+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-announces-us-fda-clearance-of-ind-for-jbi-778 2026-05-20T01:46:58+00:00 0.8 https://www.jubilanttx.com/about-us/news/the-wistar-institute-and-jubilant-therapeutics-inc-find-pad4-inhibition-in-neutrophils-halts-cancer-progression-and-metastasis 2026-05-20T01:44:52+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-to-present-at-credit-suisse-and-jefferies-investor-conferences 2026-05-20T01:40:25+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-receives-orphan-drug-designation-for-jbi-802-for-acute-myeloid-leukemia-aml-and-small-cell-lung-cancer-sclc 2026-05-20T01:38:03+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-receives-orphan-drug-designation-for-the-prmt5-inhibitor-jbi-778-for-the-treatment-of-glioblastoma-multiforme-gbm 2026-05-20T01:34:08+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-incs-selective-orally-administered-pad4-inhibitor-demonstrates-activity-in-rheumatoid-arthritis-preclinical-models 2026-05-20T01:31:05+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-appoints-nadir-patel-as-an-independent-member-of-its-board-of-directors 2026-05-20T01:28:49+00:00 0.8 https://www.jubilanttx.com/about-us/news/jbi-802-initial-phase-i-data-suggests-therapeutic-potential-in-sensitizing-immunotherapy-resistant-tumors-and-in-myeloproliferative-neoplasms-with-thrombocytosis 2026-05-20T01:26:26+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials-for-jbi-802-a-corest-inhibitor-and-jbi-778-a-prmt5-inhibitor 2026-05-20T01:24:38+00:00 0.8 https://www.jubilanttx.com/about-us/news/jubilant-therapeutics-inc-appoints-daniel-j-oconnor-as-president-and-chief-executive-officer 2026-05-20T01:16:00+00:00 0.8